|
|
|
|
| LEADER |
01797nam a2200193Ia 4500 |
| 001 |
10.1016-j.jecr.2022.100113 |
| 008 |
220510s2022 CNT 000 0 und d |
| 020 |
|
|
|a 22146245 (ISSN)
|
| 245 |
1 |
0 |
|a Thyroid dysfunction induced by alectinib in a patient with a non-small cell lung cancer
|
| 260 |
|
0 |
|b Elsevier Inc.
|c 2022
|
| 856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1016/j.jecr.2022.100113
|
| 520 |
3 |
|
|a Background: Hypothyroidism is a well-known side effect associated with tyrosine kinase inhibitors (TKIs) therapy. We describe a case of a patient with a history of postsurgical hypothyroidism who presented TSH elevation ranging from 1.68 to 17.09 IU/ml with normal free thyroxine (T4) after starting treatment with alectinib for non-small cell lung cancer (NSCLC). Case presentation: A 78-year-old female, with past medical history of Graves’ disease with subsequent total thyroidectomy and residual postsurgical hypothyroidism, was diagnosed with non-small cell lung cancer (NSCLC) and presented with TSH elevation with normal free T4 after starting therapy with alectinib. Conclusion: The most likely etiology for TSH elevation during her therapy with alectinib is an increased requirement of thyroid hormone secondary to increase activity of type 3 deiodinase and/or inhibition of monocarboxylate transporter 8 (MCT8) with consequent lower tissue availability of active T3. Further studies of thyroid dysfunction after alectinib administration are lacking. © 2022 The Authors
|
| 650 |
0 |
4 |
|a Alectinib
|
| 650 |
0 |
4 |
|a Thyroid dysfunction
|
| 650 |
0 |
4 |
|a Tyrosine kinase inhibitors (TKIs)
|
| 700 |
1 |
|
|a Henriquez, F.
|e author
|
| 700 |
1 |
|
|a Plaza-Enriquez, L.
|e author
|
| 700 |
1 |
|
|a Sanchez-Valenzuela, M.
|e author
|
| 773 |
|
|
|t Journal of Clinical and Translational Endocrinology: Case Reports
|
